Trial Search Results

Dakin's Solution in Preventing Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy

This pilot clinical trial studies Dakin's solution in preventing radiation dermatitis in patients with breast cancer undergoing radiation therapy. Radiation dermatitis is a skin condition in which the affected skin becomes painful, red, itchy, and blistered. Dakin's solution may help reduce dermatitis caused by radiation therapy.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Drug: Dakin's solution
  • Radiation: radiation therapy
  • Other: questionnaire administration
  • Other: laboratory biomarker analysis

Phase:

Phase 2

Eligibility


Inclusion Criteria:

   - Women with breast cancer who plan to undergo radiation therapy to the breast or chest
   wall

   - Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

   - Women with scleroderma or discoid lupus

   - Women with inflammatory breast cancer as evidenced by clinical assessment

   - Women with breast cancer involving the skin

   - Women who have undergone prior radiotherapy to the chest wall and/or breast

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

Female

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Amanda Simmons
650-724-4606
Recruiting